Tyra Biosciences tests oral treatment aiming to lower management burden in NMIBC

Tyra Biosciences tests oral treatment aiming to lower management burden in NMIBC
Tyra Biosciences launches SURF302 study

Tyra Biosciences has initiated the SURF302 study, focusing on an investigational oral therapeutic approach for patients with non-muscle invasive bladder cancer (NMIBC).

The company aims to reduce the treatment burden for these patients by rethinking the standard management of IR-NMIBC, potentially unlocking new possibilities in care. The SURF302 study will assess the efficacy and safety of this innovative oral therapy, offering hope for improved patient outcomes.

Tyra Biosciences has recently intensified its focus on novel therapies for urologic cancers, engaging clinical experts and patient advocates in research initiatives. The company’s efforts in this area were outlined in prior coverage of its strategy for urologic cancer treatment innovation. These moves form part of its broader pipeline targeting bladder and other urologic malignancies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.